<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.136619.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Case Report</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Case Report: Case report: Effect of intraovarian platelet-rich plasma therapy on latent female genital tuberculosis patient</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 2 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Dutta</surname>
                        <given-names>Shilpa</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-0759-1133</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>More</surname>
                        <given-names>Akash</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Funding Acquisition</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-9958-1479</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Choudhari</surname>
                        <given-names>Namrata</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Shrivastava</surname>
                        <given-names>Deepti</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Anjankar</surname>
                        <given-names>Vaibhav</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Clinical Embryology, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, 442001, India</aff>
                <aff id="a2">
                    <label>2</label>Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Wardha, Maharashtra, 442001, India</aff>
                <aff id="a3">
                    <label>3</label>Anatomy, Jawaharlal Nehru Medical College, Wardha, Maharashtra, 442001, India</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:akash.more@dmiher.edu.in">akash.more@dmiher.edu.in</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>20</day>
                <month>6</month>
                <year>2023</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2023</year>
            </pub-date>
            <volume>12</volume>
            <elocation-id>716</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>13</day>
                    <month>6</month>
                    <year>2023</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Dutta S et al.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/12-716/pdf"/>
            <abstract>
                <p>Latent female genital tuberculosis (FGTB) has been gaining attention in the world of assisted reproductive technology due to its adverse effect on the female reproductive system, which is becoming a cause of concern in the pathway of fulfilling the dream of children in infertile couples. It has been known to severely affect the ovarian reserve, which is one of the prime causes of infertility in females nowadays. Intraovarian plasma-rich platelet therapy (IOPRP) has been known to improve diminished ovarian reserve (DOR); however, its effect on DOR caused due to latent FGTB is not known. A 34-year-old middle-aged South Asian woman was unable to get pregnant due to being a victim of latent female genital tuberculosis. The patient also had a history of four failed IUI (intra-uterine insemination) cycles prior to their visit to Wardha Test Tube Baby Centre, Sawangi, Maharashtra, in January 2021. The patient had reported having improved ovarian reserve, thereby having positive clinical pregnancy upon the administration of IOPRP at our centre. This case report throws light on the aspect that the use of IOPRP on patient suffering from DOR caused due to latent FGTB may lead to significant positive pregnancy outcomes.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Endometrium</kwd>
                <kwd>Poor ovarian reserve</kwd>
                <kwd>Dilation and Curettage</kwd>
                <kwd>Oocyte</kwd>
                <kwd>Embryo.</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1" sec-type="intro">
            <title>Introduction</title>
            <p>Assisted reproductive techniques have long addressed the ongoing problems in regards to infertility in the world. We have come across various methodologies to strategically handle the root cause of infertility and provide a suitable solution to it. Worldwide, it has been reported that more than 180 million couples are suffering from infertility.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup> Several factors, like thin endometrium, poor ovarian reserve, uterine polyps, 
                <italic toggle="yes">etc.</italic>, are responsible for causing infertility.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> Out of all the problems, the current trending factor is female genital tuberculosis (FGTB). FGTB is a type of extrapulmonary tuberculosis that has been seeing an increase in trend in young females globally, especially in developing countries.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> As per the global tuberculosis report, it has been estimated that around 25% of the world&#x2019;s populace suffers from latent TB, which means they&#x2019;re asymptomatic despite exposure to the TB pathogen 
                <italic toggle="yes">Mycobacterium tuberculosis.</italic>
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> Endometrial development has reportedly been affected due to the manifestation of TB, which is known to increase harmful cytokines in the decidual layer of the uterus. The descending order of damage caused in the female genital system by FGTB is oviduct (90&#x2013;100%), hystera (70%), ovaries (30%), cervix (10%) and rarely in the vagina and valvular region (&lt;1%).
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> This is known to cause a decrease in ovarian reserve, which decreases AFC (antral follicular count), followed by low AMH (anti-Mullerian hormone) value, an endometrial lining aberration in the female reproductive region, which leads to infertility.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup>
            </p>
            <p>Instillation of intraovarian platelet-rich plasma therapy (IOPRP) in ovaries has been reported to improve ovarian reserve and enhance AFC and AMH levels, promoting the chances of a successful pregnancy.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> This case report has been made to highlight the effect of IOPRP on a patient suffering from latent FGTB.</p>
        </sec>
        <sec id="sec2">
            <title>Case presentation</title>
            <sec id="sec3">
                <title>Particulars related to the patient</title>
                <p>This case study is based on a middle-aged South Asian couple who selected Wardha Test Tube Baby Centre, Sawangi (M), India, in January 2021 to fulfil their pregnancy dream, hindered by infertility. A 34-year-old middle-aged South Asian woman suffering from secondary infertility for two years out of three years of married life was enrolled for three 
                    <italic toggle="yes">in vitro</italic> fertilisation (IVF) cycles at WTTBC, Wardha. The couple was vividly counselled about the procedure, and duly informed consent was taken from them. The husband was a lecturer by profession, and the wife was a staff nurse. Both parties have no history of smoking, drinking or any addictions.</p>
            </sec>
            <sec id="sec4">
                <title>Medical, family and psychosocial history of the couple</title>
                <p>This study gyrates around a woman who was nulligravida. They had no sexual complications in their three years of marital life. She was suffering from secondary infecundity for two years. Semen analysis of the male partner revealed the total sperm count to be 13 million/mL, which is below the lower reference limit as mentioned in WHO 2021 Guidelines.
                    <sup>
                        <xref ref-type="bibr" rid="ref6">6</xref>
                    </sup> The male partner was diagnosed with mild oligospermia. The normal morphology of sperm was reported to be 10%.</p>
                <p>The patient was diagnosed with a left ovarian cyst in 2019 and suffered from extrapulmonary tuberculosis, validated by a positive Z.N. Stain report in 2021. Tuberculosis mainly affected her endometrium, causing adhesions along with a milder effect on her ovaries. She also had a history of hypothyroidism for the past year. She was under regular medication of thyroid tablet of 125 &#x03bc;g for the last year. In 2022, between the IVF treatment at WTTBC, Wardha, she also suffered from asymptomatic Covid-19, diagnosed by taking an RT-PCR test, which came to be positive. The couple&#x2019;s family pedigree was also reported to have hypertension.</p>
                <p>The couple also had a history of undergoing IUI (intra-uterine insemination) treatment four times before visiting WTTBC, Wardha. All attempts of IUI failed prior to their IVF treatment at WTTBC, Wardha.</p>
            </sec>
            <sec id="sec5">
                <title>Clinical findings of the patient</title>
                <p>AMH (anti-Mullerian hormone) is an essential biomarker to gauge the ovarian reserve present in women.
                    <sup>
                        <xref ref-type="bibr" rid="ref7">7</xref>
                    </sup> The usual range of serum AMH to predict a healthy ovarian reserve is 2 to 6.8 ng/mL.
                    <sup>
                        <xref ref-type="bibr" rid="ref7">7</xref>
                    </sup> In our case study, the value of the serum AMH of the patient was 0.4, which is indicative of a meagre ovarian reserve. The patient's hormonal profile was found to be TSH (thyroid stimulating hormone) 18.09 mIU/L; FSH (follicle stimulating hormone) 4.99 mIU/mL; estrogen 99.319 pg/mL; and LH (luteinizing hormone) 8.97 IU/mL. Upon the use of thyroid supplement tablet of 125 &#x03bc;g for a year, the TSH value was brought down to 3.69 mIU/L. She also had a history of undergoing a diagnostic procedure, dilation and curettage (D&amp;C), with histopathology of the endometrium two years ago to understand the endometrial pathology.</p>
                <p>In the first cycle of IVF Treatment, we tried to do a fresh embryo transfer using the self-oocytes of the patient. Gonadotrophin releasing hormone (GnRH) antagonist protocol was followed for the patient. Post this, we administered 10.000 IU of human chorionic gonadotrophin (HCG) injection subcutaneously to the patient, which is responsible for oocyte maturation. We tried to do transvaginal ovum pick-up 36 hours after the injection application. However, no oocytes were found during the procedure.</p>
                <p>The couple was counselled on the following condition, and they were prepared for a second round of IVF treatment. Antral follicular count (AFC) is an effective parameter for analysing ovarian health. The patient reported having 1&#x2013;2 follicular counts in both ovaries. Lower AFC indicates poor ovarian reserve.
                    <sup>
                        <xref ref-type="bibr" rid="ref5">5</xref>
                    </sup> We planned to administer IOPRP on both the ovaries for the second round of treatment. We advised the patient to have coenzyme Q10, dehydroepiandrosterone and melatonin combined tablet once a day, and alfacalcidol 0.5 &#x03bc;g and astaxanthin 8 mg combined pill once a day. From day 2 of the menstrual cycle, we started administering minimal ovarian stimulation protocol using 100 mg of clomiphene citrate till day 6. From day 3, 150&#x2013;225 units of hMG (human menopausal gonadotrophin) were administered to the patient until one follicle reached 17&#x2013;18 mm in size. On ovulation day, we performed oocyte retrieval on the patient. We prepared the IOPRP sample by withdrawing 15 mL of venous blood from the patient in a conical tube. At first, we centrifuge the sample for 10 minutes under 1200 rpm (190&#x00d7;g). The blood is segregated into three layers. The supernatant and the buffy coat (which is believed to have concentrated platelets) were pipetted into a different conical tube and centrifuged for 10 mins under 2000 rpm (535&#x00d7;g). 4 mL of supernatant, which is our PRP sample was collected with the plan of instilling 1&#x2013;1.5 mL of the sample per ovary. The aspiration procedure was undertaken transvaginally using guided ultrasound by administering mild anaesthesia to the patient. After removing the dominant follicle, we instilled IOPRP in the collapsed follicle for around 45 seconds. We used 1&#x2013;1.5 mL of PRP for both ovaries. AFC was recorded as 1 in the right ovary and 2 in the left. Upon subsequent follow-up, we performed the oocyte aspiration procedure again, and IOPRP was followed for round 2. Upon the final aspiration procedure, we were able to retrieve 5 MII Oocytes from the patient. We planned to do a fresh embryo transfer with two embryos and freeze the rest of the embryos for frozen embryo transfer. We performed a fresh embryo transfer on the patient. &#x03b2;-HCG report performed after two weeks of the transfer resulted in negative. The couple was counselled and prepared for a frozen embryo transfer.</p>
                <p>During the subsequent visit to our centre, we analysed the thickness of the endometrium. The usual range of endometrium is above 7 mm for the transfer of embryos.
                    <sup>
                        <xref ref-type="bibr" rid="ref8">8</xref>
                    </sup> She was started with oestradiol 2 mg tablet twice daily, vitamin supplements and thyroxine 125 &#x03bc;g as a part of pre-medication.</p>
                <p>A globally approved thawing kit was used to thaw the embryo and was stored in a benchtop incubator for around 130 mins for the blastocyst to expand. Once the agenda was achieved, we transferred one embryo of 4AA grade (
                    <xref ref-type="fig" rid="f1">Figure 1</xref>) into the uterus. The patient had no discomfort using the procedure in August 2022.</p>
                <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                    <label>Figure 1. </label>
                    <caption>
                        <title>This shows the embryo that was transferred to the patient.</title>
                    </caption>
                    <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/149763/71de183f-f540-4906-9f76-07460a74c33d_figure1.gif"/>
                </fig>
            </sec>
            <sec id="sec6">
                <title>Follow-up diagnostic evaluation and therapeutic applications</title>
                <p>After the successful transfer of the embryo, the patient was discharged with the advice of follow-up. The patient was advised to have ofloxacin and ornidazole combined tablet twice daily, omeprazole 40 mg on an empty stomach daily, vitamin E supplement once a day, arginine tablet once a day, vitamin supplements, oestradiol 2 mg tablet twice a day and progesterone 400 mg once a day. She was also advised to injectables of human chorionic gonadotrophin (HCG), hydroxyprogesterone 500 mg and intralipid injection. After two weeks from the day of embryo transfer, we drew a syringe of blood from the patient and sent it for a &#x03b2;-HCG test at our laboratory centre in ABVRH, Sawangi Wardha. The report came to be positive. The level of &#x03b2;-HCG was reported to be 1050 mIU/mL.</p>
            </sec>
        </sec>
        <sec id="sec7" sec-type="discussion">
            <title>Discussion</title>
            <p>Farimani et al. (2021) did a retrospective study on the effect of oocyte variables upon the administration of IOPRP on patients affected by DOR (diminished ovarian reserve) and reportedly found significant positive results.
                <sup>
                    <xref ref-type="bibr" rid="ref9">9</xref>
                </sup> On a similar line, Parikh et al. (2022) conducted a prospective cohort study to analyse the effect on pregnancy outcome on the instillation of IOPRP in young Indian women suffering from infertility due to poor ovarian reserve (POR) and found a significant positive effect.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> This research formed the basis of our application of IOPRP in our case. The limitation of this case report is that it is performed on a single patient, and the result of this report cannot be generalised in the population. This requires further validation 
                <italic toggle="yes">via</italic> RCTs (randomised clinical trials) to form baseline treatment in latent FGTB patients seeking IVF treatment.</p>
            <p>Due to extrapolating frequency of increase in infertility across the world, it has become a matter of great importance for scientists to research its reasons and fight back with suitable outcomes to continue the human race. There are several reported reasons for infertility found in both males and females, such as low sperm count, sexual dysfunction, aspermia, teratozoospermia etc for men and uterine adhesions, hostile uterine environment, cystic ovary, blocked fallopian tubes etc for females.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup> Latent FGTB has been reported as one of the factors of infertility and caught an upward rising trend for affecting the dreams of several infertile couples desiring for a child.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> In our case study, the patient was suffering from secondary infertility due to being affected by latent FGTB. Hence, we instigated a venture to study the effect of latent FGTB on the fertility of females and find a possible solution for it. Our patient was in her middle age and was nulligravida; therefore, chances of a normal pregnancy using her own gametes seem to be a feasible option. Latent FGTB is an external form of tuberculosis. It is found to affect the fallopian tube majorly, followed by the uterus, cervix, vagina and slight chances of the valvular region.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> In our patient, latent FGTB was found to affect her ovarian reserve, thereby causing a diminished ovarian content as well as uterine adhesions presented in the case upon histopathological examination of the endometrium. We discovered several studies which show significantly positive improvement of the ovarian reserve upon the administration of IOPRP in case of poor ovarian response patients.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> However, there were no studies available on the application of IOPRP in DOR cases which was caused by latent FGTB. It has been reported in some literature that there are several growth factors in PRP that play a vital role in regulating vascular activation and neoangiogenesis by either activating the latent oocytes or stimulating the dormant ovarian stem cells to differentiate and develop into active oocytes.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> Growth factors (GFs) like VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) are important angiogenesis molecules present in PRP, which helps in the vascularisation of granulosa, thereby developing the pioneer corpus luteum into its functionality.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> Other GFs like BMP-2, BMP-4 and GDF-5 also play an essential role in developing oocyte competency by stimulating the mesenchymal and progenitor stem cells. This is believed to improve the pregnancy rate.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup>
            </p>
            <p>It is also hypothesised by some literature that follicular rupture causes injury to the ovarian epithelium, which activates the stem cells in this region to promote healing. Administration of IOPRP by the needle is thought to be activating a similar effect in the ovaries which improves the AFC in further ovum pick-up.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup>
            </p>
            <p>In our case report, we found that the instillation of IOPRP does improve the AFC in our patient suffering from DOR. We were able to retrieve healthy 5 MII oocytes, which led to a fruitful, positive clinical pregnancy outcome for the patient. This was validated by a positive &#x03b2;-HCG report.</p>
        </sec>
        <sec id="sec8" sec-type="conclusion">
            <title>Conclusion</title>
            <p>This case report outlines the upbeat sequel of the instillation of IOPRP in the case of a patient suffering from secondary infertility due to the adverse effects of latent female genital tuberculosis on her endometrium and ovaries, thereby resulting in successful clinical pregnancy with the assistance of 
                <italic toggle="yes">in vitro</italic> fertilisation (IVF) procedure at WTTBC, Wardha, India. This case also throws light on the fact that IOPRP may have a significant positive effect on the utilisation on patients suffering from genital tuberculosis.</p>
        </sec>
        <sec id="sec9">
            <title>Consent</title>
            <p>Written informed consent was obtained from the patient and her partner for the publication of their clinical details and clinical images.</p>
        </sec>
    </body>
    <back>
        <sec id="sec12" sec-type="data-availability">
            <title>Data availability</title>
            <p>All data underlying the results are available as part of the article, and no additional source data are required.</p>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ombelet</surname>
                            <given-names>W</given-names>
                        </name>
</person-group>:
                    <article-title>Global access to infertility care in developing countries: a case of human rights, equity and social justice.</article-title>
                    <source>

                        <italic toggle="yes">Facts Views Vis. ObGyn.</italic>
</source>
                    <year>2011</year>;<volume>3</volume>(<issue>4</issue>):<fpage>257</fpage>&#x2013;<lpage>266</lpage>.
                    <pub-id pub-id-type="pmid">24753875</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="book">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Walker</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tobler</surname>
                            <given-names>K</given-names>
                        </name>
</person-group>:
                    <source>

                        <italic toggle="yes">Female Infertility. [Updated 2022 Dec 19].</italic>
</source>
                    <publisher-loc>Treasure Island (FL)</publisher-loc>:
                    <publisher-name>StatPearls</publisher-name>;<year>2023</year>.
                    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK556033/">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kesharwani</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mohammad</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pathak</surname>
                            <given-names>P</given-names>
                        </name>
</person-group>:
                    <article-title>Tuberculosis in the Female Genital Tract.</article-title>
                    <source>

                        <italic toggle="yes">Cureus.</italic>
</source>
                    <year>2022 Sep 2 [cited 2023 May 21]</year>;<volume>14</volume>:<fpage>e28708</fpage>.
                    <pub-id pub-id-type="pmid">36204039</pub-id>
                    <pub-id pub-id-type="doi">10.7759/cureus.28708</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9527183</pub-id>
                    <ext-link ext-link-type="uri" xlink:href="https://www.cureus.com/articles/109199-tuberculosis-in-the-female-genital-tract">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jirge</surname>
                            <given-names>PR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chougule</surname>
                            <given-names>SM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Keni</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Latent genital tuberculosis adversely affects the ovarian reserve in infertile women.</article-title>
                    <source>

                        <italic toggle="yes">Hum. Reprod.</italic>
</source>
                    <year>2018 Jul 1 [cited 2023 May 21]</year>;<volume>33</volume>(<issue>7</issue>):<fpage>1262</fpage>&#x2013;<lpage>1269</lpage>.
                    <pub-id pub-id-type="pmid">29897442</pub-id>
                    <pub-id pub-id-type="doi">10.1093/humrep/dey117</pub-id>
                    <ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/humrep/article/33/7/1262/5036095">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Parikh</surname>
                            <given-names>FR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sawkar</surname>
                            <given-names>SG</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Agarwal</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A novel method of intraovarian instillation of platelet rich plasma to improve reproductive outcome in young Indian women with diminished ovarian reserve.</article-title>
                    <source>

                        <italic toggle="yes">Glob. Reprod. Health.</italic>
</source>
                    <year>2022 [cited 2023 May 21]</year>;<volume>7</volume>(<issue>2</issue>):<fpage>e59</fpage>&#x2013;<lpage>e59</lpage>.
                    <pub-id pub-id-type="doi">10.1097/GRH.0000000000000059</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chiu</surname>
                            <given-names>YH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Edifor</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rosner</surname>
                            <given-names>BA</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>What Does a Single Semen Sample Tell You? Implications for Male Factor Infertility Research.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Epidemiol.</italic>
</source>
                    <year>2017 Oct 15</year>;<volume>186</volume>(<issue>8</issue>):<fpage>918</fpage>&#x2013;<lpage>926</lpage>.
                    <pub-id pub-id-type="pmid">28541378</pub-id>
                    <pub-id pub-id-type="doi">10.1093/aje/kwx169</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5860180</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Dayal</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sagar</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chaurasia</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Anti-Mullerian Hormone: A New Marker of Ovarian Function.</article-title>
                    <source>

                        <italic toggle="yes">J. Obstet. Gynecol. India.</italic>
</source>
                    <year>2014 Apr [cited 2023 May 21]</year>;<volume>64</volume>(<issue>2</issue>):<fpage>130</fpage>&#x2013;<lpage>133</lpage>.
                    <pub-id pub-id-type="pmid">24757342</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s13224-013-0482-3</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3984648</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wang</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhu</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sun</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Ideal embryo transfer position and endometrial thickness in IVF embryo transfer treatment.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Gynecol. Obstet.</italic>
</source>
                    <year>2018 Dec [cited 2023 May 21]</year>;<volume>143</volume>(<issue>3</issue>):<fpage>282</fpage>&#x2013;<lpage>288</lpage>.
                    <pub-id pub-id-type="pmid">30238667</pub-id>
                    <pub-id pub-id-type="doi">10.1002/ijgo.12681</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Farimani</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nazari</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mohammadi</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: A retrospective study according to the POSEIDON criteria.</article-title>
                    <source>

                        <italic toggle="yes">Reprod. Biol. Endocrinol.</italic>
</source>
                    <year>2021 Dec [cited 2023 May 21]</year>;<volume>19</volume>(<issue>1</issue>):<fpage>137</fpage>.
                    <pub-id pub-id-type="pmid">34496887</pub-id>
                    <pub-id pub-id-type="doi">10.1186/s12958-021-00826-w</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8425058</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="book">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Leslie</surname>
                            <given-names>SW</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Soon-Sutton</surname>
                            <given-names>TL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>MA</given-names>
                        </name>
</person-group>:
                    <chapter-title>Male Infertility.</chapter-title>
                    <source>

                        <italic toggle="yes">StatPearls.</italic>
</source>
                    <publisher-loc>Treasure Island (FL)</publisher-loc>:
                    <publisher-name>StatPearls Publishing</publisher-name>;<year>2023 [cited 2023 May 21]</year>.
                    <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK562258/">Reference Source</ext-link>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report267756">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.149763.r267756</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Mamah</surname>
                        <given-names>Johnbosco</given-names>
                    </name>
                    <xref ref-type="aff" rid="r267756a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-9039-0238</uri>
                </contrib>
                <aff id="r267756a1">
                    <label>1</label>University of Nigeria, Nsukka, Enugu, Nigeria</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>2</day>
                <month>5</month>
                <year>2024</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Mamah J</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport267756" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.136619.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This was a very interesting case report highlighting the role of IOPRP treatment in the management of DOR in subfertile individuals whose infertility may have been caused by genital tuberculosis. The use of platelet-rich plasma in medical practice remains an evolving area of medical research, and it is gratifying to see its use being expanded into new areas.&#x00a0;</p>
            <p> </p>
            <p> I find that the patient's medical history was not detailed enough, thereby leaving a few unanswered questions. For instance, the diminished Ovarian reserve in the patient could have been caused by many factors, including the Ovarian cyst the patient had. It is not clear the nature of the cyst and any treatment received for the cyst. Cystectomies may lead to diminished ovarian reserve, which can impact fertility. If there was no treatment, the authors should clarify.&#x00a0;</p>
            <p> </p>
            <p> The authors state that the patient had secondary infertility, yet she is described as nulligravida. This is confusing. What was the nature of the infertility? Has she ever been pregnant or had a child in the past?&#x00a0;</p>
            <p> </p>
            <p> It is not clear which came first: endometrial adhesions or D/C. D/C is a risk factor for endometrial adhesions, so it may not have been due to genital TB. The authors did not clarify if the tuberculosis was treated. How did we establish that the patient had TB of the ovary? Was ovarian fluid aspirate/tissue tested for M-TB? How did the authors establish a cause-and-effect relationship between DOR and genital TB?</p>
            <p> </p>
            <p> The patient was significantly hypothyroid, was the treatment she had contributory to the positive outcome?</p>
            <p> </p>
            <p> Although the patient had a positive pregnancy test in the end, what was the final outcome of the pregnancy?&#x00a0;</p>
            <p> </p>
            <p> The authors used many unconventional terms/words, which is not typical of scientific writing.</p>
            <p>Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?</p>
            <p>Partly</p>
            <p>Is the case presented with sufficient detail to be useful for other practitioners?</p>
            <p>Yes</p>
            <p>Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?</p>
            <p>No</p>
            <p>Is the background of the case&#x2019;s history and progression described in sufficient detail?</p>
            <p>Partly</p>
            <p>Reviewer Expertise:</p>
            <p>Benign Gynaecology</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report203100">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.149763.r203100</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Dogra</surname>
                        <given-names>Yogita</given-names>
                    </name>
                    <xref ref-type="aff" rid="r203100a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-8102-0262</uri>
                </contrib>
                <aff id="r203100a1">
                    <label>1</label>All India Institute of Medical Sciences, Delhi, India</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>30</day>
                <month>10</month>
                <year>2023</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Dogra Y</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport203100" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.136619.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>The present case report has highlighted the effect of TB on ovarian reserve and the effect of IOPRP in improving the same. The patient is a 38 year old woman with low AMH and low AFC with previous history of extrapulmonary TB and four failed IUI cycles. The ovarian reserve improved after two subsequent rounds of IOPRP instillation. Subsequently patient conceived in FET cycle.</p>
            <p> </p>
            <p> The background of case history and the progression should be made more clearer. The nature of cyst diagnosed in 2019 is not mentioned e.g. endometriotic cysts are known to decrease the ovarian reserve. The authors have mentioned that FGTB has led to decrease in ovarian reserve in this case. However it is difficult to reach this conclusion keeping in mind the age of the patient and the presence of ovarian cyst.</p>
            <p> </p>
            <p> Whether patient took ATT for Extrapulmonary TB diagnosed in 2021 needs to be mentioned.&#x00a0;</p>
            <p> </p>
            <p> What was the AFC in first IVF cycle? Any supplements were advised before IVF to improve the ovarian reserve? Please elaborate.</p>
            <p> </p>
            <p> Please provide the reference for IOPRP instillation in a stimulated cycle. Can it be instilled in a natural cycle?</p>
            <p> </p>
            <p> It has also not been mentioned whether again ovarian stimulation was done for second round of IOPRP.</p>
            <p> </p>
            <p> Before final aspiration, please mention the AFC. Whether IVF protocol was used and which protocol in which 5 MII oocytes were retrieved.&#x00a0;</p>
            <p> </p>
            <p> What was the ET during FET cycle as uterine adhesions have also been mentioned? Did the patient receive any treatment or hysteroscopy advised for adhesions? The detailed methodology in step wise manner would be more helpful for the readers and the other practitioners to understand the positive effect of IOPRP in improving the ovarian reserve.</p>
            <p>Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?</p>
            <p>Partly</p>
            <p>Is the case presented with sufficient detail to be useful for other practitioners?</p>
            <p>Partly</p>
            <p>Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?</p>
            <p>Yes</p>
            <p>Is the background of the case&#x2019;s history and progression described in sufficient detail?</p>
            <p>Partly</p>
            <p>Reviewer Expertise:</p>
            <p>Reproductive Medicine</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
    </sub-article>
</article>
